BLLN Stock Analysis: Buy, Sell, or Hold?
$105.90
0.14 (0.13%)
▲
5d:
-13.96%
30d:
+10.14%
90d:
-14.18%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When BLLN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BLLN is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BLLN is down 14.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$3.84
Based on -31.5% avg growth
INTRINSIC VALUE TODAY
$2.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BLLN is currently trading at $105.90, which is considered fair relative to its 30-day fair value range of $94.90 to $113.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 71.3) compared to its historical average (113.7). Remarkably, the market is currently pricing in an annual earnings decline of 14.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BLLN is showing sideways momentum. The price is currently testing key support at $102.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $128.57 (+21.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BLLN is showing sideways momentum. The price is currently testing key support at $102.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $128.57 (+21.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$94.90 -
$113.42
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.7%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.4% below Wall St target ($128.57)
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$94.90 -
$113.42
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$9.31
(8.8%)
Support & Resistance Levels
Support Level
$102.75
Resistance Level
$127.72
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
71.31
Wall Street Target
$128.57
(+21.4%)
Revenue Growth (YoY)
64.4%
Profit Margin
8.3%
Valuation Discount vs History
-14.4% cheaper
PE vs Historical
71.3 vs 113.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.4%
(market-implied from PE analysis)
1-Year Target
$95.31
(-10%)
2-Year Target
$85.78
(-19%)
3-Year Target
$77.20
(-27%)
3-Yr Target (if PE normalizes)
(PE: 71→114)
$123.09
(+16%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 71.3, Growth: -66.9%)
$103.79
(+-2%)
Base:
(SPY PE: 20.4, Growth: -66.9%)
$29.69
(-72%)
Bear:
(PE: 17.3, Growth: -66.9%)
$25.24
(-76%)
📈
Valuation based on Current Earnings
Forward PE: 69.93 | Forward EPS (Implied): $1.51
Bull Case
$127.71
(+21%)
Analyst growth 15.0%, PE expands to 73.4
Base Case
$105.76
(0%)
Market implied 0.0%, PE stable at 69.9
Bear Case
$80.91
(-24%)
Severe decline -15.0%, PE contracts to 62.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 71.3 to 113.7
Stabilization Target:
$168.84
(+59.4%)
PE Expansion Potential:
+59.4%
Share & Embed Analysis
Last updated: October 02, 2026 5:46 PM ET
Data refreshes hourly during market hours. Next update: 6:46 PM
Data refreshes hourly during market hours. Next update: 6:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BLLN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$653 | 49 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$231 | 53 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 48 HOLD |
|
LH
Laboratory Corporation o… |
STRONG BUY
20 analysts |
$345 | 67 BUY |